Search Results - "Wong, Chew Hooi"

Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation by Wong, Chew Hooi, Iskandar, Kartini Bte, Yadav, Sanjiv Kumar, Hirpara, Jayshree L, Loh, Thomas, Pervaiz, Shazib

“…Chemotherapy-induced reduction in tumor load is a function of apoptotic cell death, orchestrated by intracellular caspases. However, the effectiveness of these…”
Get full text

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial by Soo, Ross A., Huat Tan, Eng, Hayashi, Hidetoshi, Seto, Takashi, Lin, Chia-Chi, Ou, Sai-Hong Ignatius, Kim, Dong-Wan, Liu, Geoffrey, Abbattista, Antonello, Martini, Jean-François, Hooi Wong, Chew, Toffalorio, Francesca, Solomon, Benjamin J.

“…•Substantial activity was observed in both Asian and non-Asian pretreated patients.•AE profiles were comparable between Asian and non-Asian…”
Get full text

Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis by Lee, Shuet Theng, Feng, Min, Wei, Yong, Li, Zhimei, Qiao, Yuanyuan, Guan, Peiyong, Jiang, Xia, Wong, Chew Hooi, Huynh, Kelly, Wang, Jinhua, Li, Juntao, Karuturi, K. Murthy, Tan, Ern Yu, Hoon, Dave S. B., Kang, Yibin, Yu, Qiang

“…Efforts to improve the clinical outcome of highly aggressive triple-negative breast cancer (TNBC) have been hindered by the lack of effective targeted…”
Get full text

Correction: Simultaneous Induction of Non-Canonical Autophagy and Apoptosis in Cancer Cells by ROS-Dependent ERK and JNK Activation by Wong, Chew Hooi, Iskandar, Kartini Bte, Yadav, Sanjiv Kumar, Hirpara, Jayshree L, Loh, Thomas, Pervaiz, Shazib

“…[This corrects the article DOI: 10.1371/journal.pone.0009996.]…”
Get full text

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC by Zhou, Qing, Soo, Ross A., Chang, Gee-Chen, Chiu, Chao-Hua, Hayashi, Hidetoshi, Kim, Sang-We, Teraoka, Shunsuke, Goto, Yasushi, Zhou, Jianying, Ho-Fun Lee, Victor, Kim, Dong-Wan, Han, Baohui, Chung Man Ho, James, Lin, Chia-Chi, Lu, Shun, Polli, Anna, Calella, Anna Maria, Martini, Jean-François, Wong, Chew Hooi, Mok, Tony, Kim, Hye Ryun, Wu, Yi-Long

“…Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial…”
Get full text

Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond by Furtner, Daniel, Shinde, Salil Prakash, Singh, Manmohan, Wong, Chew Hooi, Setia, Sajita

“…A number of developments, including increasing regulatory and compliance scrutiny, increased transparency expectations, an increasingly vocal patient, patient…”
Get full text

Redefining the Role of Medical Affairs Professionals as Innovators and Leaders in Industry-Led Medical Education by Setia, Sajita, Loo, Elliot, Shinde, Salil Prakash, Singh, Manmohan, Wong, Chew Hooi, Thakkar, Karan

“…Medical affairs professionals are pivotal players at the intersection of medical innovation and practice in the pharmaceutical industry. They are uniquely…”
Get full text

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050) by Cheng, Ying, Mok, Tony S., Zhou, Xiangdong, Lu, Shun, Zhou, Qing, Zhou, Jianying, Du, Yingying, Yu, Ping, Liu, Xiaoqing, Hu, Chengping, Lu, You, Zhang, Yiping, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Linke, Rolf, Wong, Chew Hooi, Tang, Yiyun, Zhu, Fanfan, Wilner, Keith D., Wu, Yi-Long

“…•1st-line dacomitinib improved OS vs gefitinib in Asian patients with advanced NSCLC.•OS benefit with dacomitinib was maintained in Asian patients with dose…”
Get full text